Aplenzin (Bupropion HBr) Patent Expiration, LOE Window & CMS Spending
Aplenzin (Bupropion HBr) by Bausch Health: FDA Orange Book LOE 2026-06-27, 32 AB generics, $40.2M 2024 CMS Part D & Medicaid spend, and 15 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Bausch Health |
| FDA Application & Pathway | N022108 (NDA) |
| Exclusivity / Cliff Horizon | Immediate Cliff (2025-2027) |
| Core Active-Ingredient LOE Date | Not listed / N/A |
| Last Listed Patent or Exclusivity Date | 2026-06-27 |
| Orange Book Patents (*PED Extensions) | 8 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 32 |
| 2024 CMS Total Public Spend | $40.2M |
| 2024 Medicare Part D Spend | $23.5M |
| 2024 Medicaid Spend | $16.7M |
| Reported Wholesale Price Change (CA SB 17) | 15 WAC filings (max 45.9% 2-yr change) |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Bausch Health / Bausch + Lomb across sibling Meru public-data platforms.
- Predicate Ledger FDA 510(k)Bausch Health / Bausch + Lomb FDA 510(k) & Recall Cohortdevices.meruai.co →
- Protocol Ledger NIH ClinicalTrials.govBausch Health / Bausch + Lomb Clinical Trials & Approvalstrials.meruai.co →
- ERISA Ledger DOL Form 5500Bausch Health / Bausch + Lomb 401(k) & Form 5500 Planerisa.meruai.co →